Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.55 |
| ▸ | PTAFR | P25105 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13644519 | 0.89 | PTPN1 (0.62) | ALDH1A1MAPTPTPN1TSHRKDM4E | |
| SCHEMBL12651372 | 0.83 | ALDH1A1 (0.46) | ALDH1A1MAPTPTPN1PTAFRTSHR | |
| SCHEMBL13644528 | 0.83 | USP2 (0.53) | ALDH1A1MAPTPTPN1PTAFRTSHR | |
| SCHEMBL13362374 | 0.83 | USP2 (0.53) | ALDH1A1MAPTPTPN1PTAFRTSHR | |
| SCHEMBL1015152 | 0.82 | MIF (0.57) | ALDH1A1MAPTPTPN1TSHRUSP2 | |
| SCHEMBL5689279 | 0.82 | TUBB4A (0.49) | MAPTPTPN1USP2L3MBTL1 | |
| SCHEMBL13660015 | 0.80 | MIF (0.51) | ALDH1A1MAPTPTPN1TSHRUSP2 | |
| SCHEMBL15463035 | 0.78 | MAPT (0.48) | ALDH1A1MAPTPTPN1TSHRUSP2 | |
| SCHEMBL6939090 | 0.77 | TSHR (0.51) | PTPN1TSHRCA2MAOB | |
| SCHEMBL5686355 | 0.77 | TUBB4A (0.52) | ALDH1A1MAPTPTPN1TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883809-B2 | Isoxazole/isoxazoline/combretastatin linked dihydroquinazolinone hybrids as potential anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-11-11 | — | — | US | disclosed |
| US-20120283439-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Redearch (IN) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283439-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | NDUFAF1, TOP1, COX4I1 | ALDH1A1 212/4885MAPT 1678/4885PTPN1 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.